4.5 Article

NCCN Guidelines® Insights Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017 Featured Updates to the NCCN Guidelines

出版社

HARBORSIDE PRESS
DOI: 10.6004/jnccn.2017.0003

关键词

-

类别

资金

  1. Astellas
  2. AstraZeneca
  3. Celldex Therapeutics
  4. Clovis Oncology
  5. Genomic Health, Inc.
  6. Kyowa Hakko Kirin
  7. Jazz Pharmaceuticals
  8. Novartis Pharmaceuticals Corporation
  9. NOVOCURE
  10. independent educational grant from Merck Co., Inc.

向作者/读者索取更多资源

The NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling for hereditary cancer syndromes and risk management recommendations for patients who are diagnosed with a syndrome. Guidelines focus on syndromes associated with an increased risk of breast and/or ovarian cancer. The NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. The NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding risk management for carriers of moderately penetrant genetic mutations associated with breast and/or ovarian cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据